Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases
    Meeting Abstract

    Le Rhun, E.; Nayak, L.; Fat, M. J. L.; Rudà, R.; Pentsova, E.; Forsyth, P.; O'Brien, B.; Preusser, M.; Kumthekar, P.; Brandsma, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • TroFuse-015: A phase III study of trophoblast antigen 2 (TROP2)—directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) vs treatment of physician's choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
    Meeting Abstract

    Shitara, K.; Wainberg, Z. A.; van Cutsem, E.; Janjigian, Y. Y.; Xu, R. H.; Oh, D. Y.; Xu, J.; Wu, S.; Bhaumik, S.; Bhagia, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase Ib/II open-label study evaluating trastuzumab deruxtecan (T-DXd) in combination with rilvegostomig and chemotherapy in patients with HER2-positive (HER2+) and HER2-low gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 Part 4
    Meeting Abstract

    Janjigian, Y. Y.; Lloyd, C.; de Giorgio-Miller, V. G.; Chang, Y. T.; Lee, J.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • 280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial
    Meeting Abstract

    Eto, M.; Motzer, R. J.; Choueiri, T. K.; Haanen, J. B. A. G.; Oya, M.; Uemura, H.; Venugopal, B.; Rini, B. I.; Miyake, H.; Albiges, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • 292P Avelumab + axitinib (A + Ax) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses by age from the final analysis of the phase III JAVELIN Renal 101 trial
    Meeting Abstract

    Oya, M.; Motzer, R. J.; Choueiri, T. K.; Haanen, J. B. A. G.; Eto, M.; Uemura, H.; Venugopal, B.; Rini, B. I.; Miyake, H.; Albiges, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Topical steroids for the prevention of radiation dermatitis in breast cancer: A systematic review and network meta-analyses of randomised controlled trials
    Meeting Abstract

    Tse, S. W.; Gojesvic, M.; Lee, S. F.; Caini, S.; Sauder, M.; Hircock, C.; Wang, A.; Chan, W.; Corbin, K.; Choi, I.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Kudo, M.; Rimassa, L.; Chan, S. L.; Sangro, B.; Lau, G.; Breder, V. V.; Varela, M.; Crysler, O. V.; Bouattour, M.; Dao, V. T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma
    Meeting Abstract

    Rha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Weber, P. E. Y.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • EDGE-Gastric Arm A1: Phase II study of domvanalimab (D), zimberelimab (Z), and FOLFOX in first-line (1L) advanced gastroesophageal (GE) cancer
    Meeting Abstract

    Rha, S. Y.; Oh, D. Y.; Pelster, M.; Wainberg, Z. A.; Sison, A.; Scott, J.; Nelson, S.; Wishengrad, D.; Rhee, J.; Nuyten, D. S. A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Kudo, M.; Lencioni, R.; Erinjeri, J.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V. V.; Bouattour, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save